Azilsartan compared to ACE inhibitors in anti-hypertensive therapy: one-year outcomes of the observational EARLY registry
| Autor: | Jochen Senges, Hartmut Buhck, Martina Ehmen, Sebastian Potthoff, Felix Mahfoud, Peter Bramlage, Peter Baumgart, Roland E. Schmieder, Anselm K. Gitt, Taoufik Ouarrak |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2016 |
| Předmět: |
Male
Azilsartan medoxomil (AZL-M) Time Factors Angiotensin-Converting Enzyme Inhibitors Effectiveness 030204 cardiovascular system & hematology Renin-Angiotensin System 0302 clinical medicine Risk Factors Medizinische Fakultät Germany Azilsartan Odds Ratio Medicine 030212 general & internal medicine Prospective Studies Registries Prospective cohort study Oxadiazoles Real world Middle Aged Treatment Outcome Tolerability Hypertension Practice Guidelines as Topic Female Safety Cardiology and Cardiovascular Medicine medicine.drug Research Article Adult medicine.medical_specialty Medication Adherence 03 medical and health sciences Internal medicine Humans Arterial Pressure ddc:610 Adverse effect Antihypertensive Agents Aged Chi-Square Distribution business.industry Odds ratio Clinical trial Blood pressure Endocrinology Multivariate Analysis Observational study Benzimidazoles business Angiotensin II Type 1 Receptor Blockers |
| Zdroj: | BMC Cardiovascular Disorders |
| Popis: | Background Azilsartan medoxomil (AZL-M), has been demonstrated to be more effective than the other sartans currently in use; however, there is insufficient information available comparing it with ACE-inhibitors. Therefore, we aimed to compare the efficacy, safety, and tolerability of AZL-M with that of ACE-inhibitors in a real life clinical setting. Methods The EARLY registry is a prospective, observational, national, multicentre registry with a follow-up period of 12 months. There were two principal objectives: 1) documentation of the achievement of target BP values set according to recent national and international guidelines, and 2) description of the safety profile of AZL-M. Results A total of 3 849 patients with essential arterial hypertension were recruited from primary care offices in Germany. Patients who initiated monotherapy at baseline comprising either AZL-M or an ACE-inhibitor were included at a ratio of seven to three. Results demonstrated that a blood pressure target of |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|